Dr. Hana Hybasek Dzurikova, MRCVS, PGCert MEd
23. September 2024

Launch of the Post-ROSC ECG Analysis using AI (PEACE AI) Validation Study

Advancing the Cardiac Chain of Survival: Detection of Occlusive Myocardial Infarction in Out-Of-Hospital Cardiac Arrest (OHCA) Patients

At Powerful Medical, we are at the forefront of innovation, and we are excited to announce the latest multi-center validation study of our AI platform, PMcardio. This study evaluates the effectiveness of our AI model (Queen of Hearts) in detecting Occlusive Myocardial Infarction (OMI) using 12-lead ECGs recorded in patients who have been resuscitated after an out-of-hospital cardiac arrest (OHCA).

Background

Diagnosing OMI after a resuscitated OHCA remains a significant challenge in emergency and cardiology settings. Although ST-Elevation Myocardial Infarction (STEMI) millimeter criteria are commonly used, acute thrombotic occlusive lesions can exist even without typical ST-elevation, making detection of STEMI difficult. This study addresses that gap by utilizing our advanced AI model to detect OMI based on 12-lead ECGs recorded immediately  post-Return of Spontaneous Circulation (ROSC).

The Need for Advanced Detection in Post-ROSC OMI Patients

The 2023 ESC guidelines for Acute Coronary Syndromes introduced new complexities in the management of OHCA patients, particularly with the recommendation against routine immediate coronary angiography (CAG) for hemodynamically stable patients without persistent ST-segment elevation or its equivalents (Class IIIA).

This change presents a challenge, as the definition of STEMI equivalents remains ambiguous, potentially leading to missed diagnoses at the critical early stages. Despite this shift, many centers continue to take a proactive approach, performing immediate CAG in OHCA cases. There remains a significant clinical need to identify patients without obvious ST-elevation who may still have an occluded artery, particularly in facilities without PCI capabilities.

Study Overview

Led by Dr. Simone Savastano at Fondazione IRCCS Policlinico San Matteo in Pavia, Italy, this study will involve key collaborators – Dr. Thomas Keeble and Dr. Uzma Sajjad at the Essex Cardiothoracic Centre, UK and Dr. Sascha Macherey and Dr. Christoph Adler at University Hospital Cologne, Germany. The analysis will include over 1,000 post-ROSC ECGs, with PMcardio’s AI predictions compared against invasive coronary angiographic findings.

Upcoming Presentations

The preliminary results of this groundbreaking study will be shared at the European Resuscitation Council Congress (Resuscitation 2024) and other leading cardiology and emergency medicine conferences throughout the year. Stay tuned for more detailed results following the conference presentations.

Stay Informed

We are excited to share the full details of this groundbreaking study with the medical community and beyond. Keep an eye on our website for further updates and insights as we continue to refine our AI models and push the boundaries of cardiovascular care.

Dr. Hana Hybasek Dzurikova, MRCVS, PGCert MEd

Dr. Hana Hybasek Dzurikova, MRCVS, PGCert MEd is a medical educator driving innovation and change in health professions education through technology-enhanced learning.
Dr. Hana Hybasek Dzurikova, MRCVS, PGCert MEd is a medical educator driving innovation and change in health professions education through technology-enhanced learning.
About PMcardio:

PMcardio is the market leader in AI-powered diagnostics, addressing the world’s leading cause of death – cardiovascular diseases. The innovative clinical assistant empowers healthcare professionals to detect up to 40 cardiovascular diseases. In the form of a smartphone application, the certified Class IIb medical device interprets any 12-lead ECG image in under 5 seconds to provide accurate diagnoses and individualized treatment recommendations tailored to each patient.

About Powerful Medical:

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Don't miss these

Advanced STEMI Detection and Improved Cath Lab Activation through ECG Transmission and Notifications

By utilizing advanced AI technology, PMcardio simplifies complex diagnostics, delivering real-time insights to support clinical decisions. Its Notification Functionality enhances communication and accelerates care delivery with manual and automated alerts, ensuring timely interventions.

Announcing the AI-ECG TIMI Study: A Multi-Center Validation

We are thrilled to announce the launch of the AI-ECG TIMI Study, a novel, international, multi-center observational study aimed at validating the use of AI to improve the detection and management of acute coronary syndromes (ACS).

Join 25,000 healthcare professionals who are already taking advantage of AI